A Cambridge biotech teaching antibodies to behave like T-cell receptors - so the immune system can finally reach the cancer targets it was never built to see.
Every tumor cell is a leaky building. Most of what makes a cancer cell dangerous happens inside it, behind a wall that conventional antibodies cannot climb. But the cell, helpfully, posts notices. It chops up its own proteins and displays the fragments on its surface, clipped into a molecular frame called the HLA. Read those fragments and you learn what the cell is hiding. That is the whole business of Crossbow Therapeutics.
Today the company is a roughly 44-person operation in Cambridge, Massachusetts, with two drugs in or near the clinic and more than $157 million in the bank. Its lead therapy, CBX-250, is already in people. Its second, CBX-663, is lining up for the clinic. None of this existed as a product a few years ago. It existed as an argument: that the list of cancer targets the industry calls "druggable" is far too short, and that the fix is an antibody that mimics the one part of the immune system designed to read those surface notices - the T-cell receptor.
It is a tidy metaphor, and like most tidy metaphors it conveniently skips the hard part. Hitting a precise target is easy to say and brutal to engineer. The question that follows Crossbow around is the only one that matters: does the science actually hit?
For decades, antibody drugs have been one of oncology's best tools. They are precise, potent, and well understood. They also share a flaw: they can only grab proteins on the outside of a cell. The trouble is that the proteins driving many cancers - the mutated oncogenes, the transcription factors, the molecular engines - sit on the inside, out of reach. Roughly speaking, the most interesting targets in cancer are the ones antibodies were never able to touch.
T cells solved this problem millions of years before biotech existed. A T-cell receptor reads those surface-displayed peptide-HLA fragments and kills the cell flagged as abnormal. Powerful - but T-cell receptors are notoriously hard to turn into manufacturable, controllable drugs. So the field was stuck between two imperfect tools: antibodies that are easy to build but blind to the inside of the cell, and T-cell receptors that can see inside but are stubborn to engineer.
Crossbow's bet is that you do not have to choose. Build an antibody that sees like a T-cell receptor, and the wall stops mattering.
The underlying biology - TCR-mimetic antibodies that recognize peptide-HLA complexes - traces back to academic research at the University of Pennsylvania's Perelman School of Medicine, where Daniel J. Powell Jr. and colleagues worked on antibodies that could read what T cells read. The company that grew around it was assembled in 2021 with co-founders including Geraldine Paulus, longtime biotech advisor Patrick Baeuerle, and investor Todd Foley of MPM BioImpact.
At the helm is Briggs Morrison, a physician and drug developer whose name carries weight in the industry. Pairing an academic discovery with a CEO known for shepherding drugs through development is not an accident. It is the bet: the idea is real, but ideas are cheap in biotech. The scarce thing is the discipline to turn one into a trial.
The engine is the T-Bolt platform: a discovery system that produces TCR-mimetic antibodies - the company calls them T-Bolt molecules - tuned to grab a specific peptide-HLA complex on a tumor and recruit a T cell to destroy it. The point of a platform, of course, is that it is supposed to keep producing. Two programs in, that claim is being tested.
The TCRm technology that generates antibodies which read peptide-HLA complexes with high accuracy and potency - reaching intracellular targets conventional antibodies cannot.
A first-in-class T-cell engager targeting a peptide-HLA complex specific to myeloid cancer cells. In the CROSSCHECK-001 trial for relapsed/refractory AML, CML, MDS and CMML. Initial data expected late 2026.
A first-in-class T-cell engager aimed at a telomerase (TERT)-derived peptide-HLA complex - a target present across many hematologic and solid tumors. IND and Phase 1 planned.
No one should confuse a financing round with a cure. A Series B is a wager on what might happen, not a record of what did. Still, the people writing these checks read clinical data for a living - and the ones who already knew Crossbow chose to write again.
The March 2026 round was co-led by Taiho Ventures and Arkin Bio Capital, both of whom took board seats. The list of backers is the kind that makes other investors look twice:
That last name matters. Blood Cancer United's Therapy Acceleration Program does not invest to diversify a portfolio; it invests to move drugs toward patients with leukemia. Its presence is a quieter endorsement than a venture check, and arguably a louder one.
Strip away the archery branding and the company's purpose is unfashionably plain: widen the set of cancer antigens medicine can actually aim at. If a tumor displays a fragment on its surface, Crossbow wants a molecule that can read it and a T cell that can act on it. The targets it has chosen first - a myeloid-specific complex, and a telomerase fragment found across many cancers - are not random. They are proofs of concept for the claim that the platform can keep going.
Return to the leaky building. For most of oncology's history, the notices a cancer cell posted on its surface were written in a language our best drugs could not read. The proteins that mattered stayed hidden, and the antibody, for all its precision, walked right past them.
Crossbow's wager is that the wall was never the real obstacle - the reading was. By the end of 2026, the first clinical data from CBX-250 should start to say whether the wager pays. If it does, the short list of "druggable" targets gets longer, and a lot of cancers that looked unreachable start to look like addresses, not fortresses.
The company is named after a weapon, but the better way to read it is older than the weapon: someone learned to read what the target was telling them, and aimed accordingly. The data will decide the rest. It usually does.
Profile compiled from public sources including the company's website, Business Wire, Endpoints News, BioPharma Dive and Blood Cancer United, as of June 2026. Figures such as revenue are approximate; clinical timelines reflect company-stated expectations and may change.